 BURLINGTON, Mass., Aug. 07, 2020 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of August 3, 2020. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635c4. The restricted stock units vest over four years, with 25 of the shares vesting on each annual anniversary of the applicable vesting commencement date, subject to the new employees continued service relationship with the Company. The restricted stock units are subject to the terms and conditions of the Companys 2013 Equity Incentive Plan and a restricted stock unit agreement covering the grant.About Flexion Therapeutics Flexion Therapeutics Nasdaq:FLXN is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Companys core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com. Contact: Scott Young Vice President, Corporate Communications Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 